Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Articles published by Evecxia Therapeutics, Inc.

News headline image
Evecxia Doses First Patient in Phase 1b Brain Target Engagement Study of Serotonin Synthesis Amplification Therapy
From Evecxia Therapeutics, Inc.
Via Business Wire
News headline image
Evecxia Provides Financing & Corporate Updates Including Plans for an EVX-101 Proof-of-Concept Phase 2 Clinical Study in Obsessive-Compulsive Disorder (OCD) Responding Inadequately to First-line Therapies
From Evecxia Therapeutics, Inc.
Via Business Wire
News headline image
Evecxia Therapeutics Strengthens Board of Directors With Appointments of Allan L. Shaw and Elliot Ehrich
From Evecxia Therapeutics, Inc.
Via Business Wire
News headline image
Evecxia Therapeutics Reports No Toxicology Findings in Nonclinical GLP Studies of Adjunctive EVX-101
From Evecxia Therapeutics, Inc.
Via Business Wire
News headline image
Evecxia Therapeutics Announces CEO Transition
From Evecxia Therapeutics, Inc.
Via Business Wire
News headline image
Evecxia Therapeutics Announces Data Presentations on Lead Candidate EVX-101 at the 2023 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting
From Evecxia Therapeutics, Inc.
Via Business Wire
News headline image
Evecxia Therapeutics Receives Notice Of Allowance For A U.S. Patent Covering Its Lead Drug Candidate EVX‑101
From Evecxia Therapeutics, Inc.
Via Business Wire
News headline image
Evecxia Therapeutics Reports Favorable Data From a Phase 1 Single-Ascending Dose and Multiple-Ascending Dose Trial of Adjunctive EVX-101 in Healthy Volunteers Treated With a First-Line Antidepressant
From Evecxia Therapeutics, Inc.
Via Business Wire
News headline image
Evecxia Therapeutics Reports Favorable Data From a Phase 1 Single Ascending Dose Safety/Tolerability/PK/PD Trial of EVX-301
From Evecxia Therapeutics, Inc.
Via Business Wire
News headline image
Evecxia Therapeutics Announces Leadership Transition to Support Next Phase of Development and Growth
From Evecxia Therapeutics, Inc.
Via Business Wire
News headline image
Evecxia Therapeutics Announces Issuance of US Patent Covering EVX-101 for Depression and Other CNS Disorders
From Evecxia Therapeutics, Inc.
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.